Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $64.3 million.

  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 19.12% to $74.5 million in Q3 2025 from the same period last year, while for Mar 2025 it was $68.1 million, marking a year-over-year increase of 38.94%. This contributed to the annual value of $64.3 million for FY2024, which is 31.03% up from last year.
  • As of FY2024, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $64.3 million, which was up 31.03% from $49.0 million recorded in FY2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $64.3 million during FY2024, and registered a low of $28.1 million during FY2020.
  • Over the past 3 years, Corvus Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $49.0 million (recorded in 2023), while the average stood at $53.3 million.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) declined by 4.57% in 2020, and later soared by 65.88% in 2021.
  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $28.1 million in 2020, then spiked by 65.88% to $46.5 million in 2021, then grew by 0.01% to $46.6 million in 2022, then rose by 5.34% to $49.0 million in 2023, then soared by 31.03% to $64.3 million in 2024.